Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”

authors:

avatar Babak Sayad ORCID 1 , * , avatar Fatemeh Norooznezhad 1 , avatar Alireza Farokhi 1

Liver Diseases Research Center, Kermanshah University of Medical Sciences, Iran
Hepatitis Monthly: Vol.17, issue 3; e58720
published online: March 8, 2017
article type: Letter
received: February 13, 2017
accepted: March 1, 2017
DOI: https://doi.org/10.5812/hepatmon.46588

how to cite: Sayad B, Norooznezhad F, Farokhi A. Comments on “The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3”. Hepat Mon. 2017;17(3):e58720. https://doi.org/10.5812/hepatmon.46588.

Acknowledgements

References

  • 1.

    Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2016;17(1). https://doi.org/10.5812/hepatmon.44564.

  • 2.

    American Association for the Study of Liver Diseases. Recommendations for Testing, Managing, and Treating Hepatitis C. 2016.

  • 3.

    E. A. S. L. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153-94. https://doi.org/10.1016/j.jhep.2016.09.001.

  • 4.

    Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63(1):20-9. [PubMed ID: 25646891]. https://doi.org/10.1016/j.jhep.2015.01.026.

  • 5.

    Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother. 2015;49(6):674-87. [PubMed ID: 25770114]. https://doi.org/10.1177/1060028015576180.

  • 6.

    Martinello M, Dore GJ, Skurowski J, Bopage RI, Finlayson R, Baker D, et al. Antiretroviral use in the Cease cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2016;3(2). https://doi.org/10.1093/ofid/ofw105.

  • 7.

    Macias J, Monge P, Mancebo M, Merchante N, Neukam K, Real LM, et al. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. HIV Med. 2016. [PubMed ID: 27882706]. https://doi.org/10.1111/hiv.12471.

  • 8.

    Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, et al. A Review of Daclatasvir Drug-Drug Interactions. Adv Ther. 2016;33(11):1867-84. [PubMed ID: 27664109]. https://doi.org/10.1007/s12325-016-0407-5.

  • 9.

    Smolders EJ, Colbers EP, de Kanter CT, Velthoven-Graafland K, Drenth JP, Burger DM. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat. J Antimicrob Chemother. 2017;72(2):486-9. [PubMed ID: 27798211]. https://doi.org/10.1093/jac/dkw429.

  • 10.

    National protecol for evaluation of patients with HIV/AIDS and antiretroviral treatment in adolescent and adults. Tehran, Iran: Ministry of Health and Medical Education, Deputy of Health, Center of Disease Control; 2014.